IL1B and cancer: The major findings are fourfold: (1) repetitive oral administration of XAT for 7 consecutive days greatly reduces bone cancer pain; (2) treatment with combination of XAT and morphine produces synergistic analgesic effects; (3) XAT can prevent or alleviate the gastrointestinal adverse reactions constipation, nausea, fatigue, and anorexia accompanied with cancer pain and/or caused by morphine treatment; and (4) XAT treatment significantly reduces the proinflammatory cytokines IL-1β and TBF-α and increases the endogenous anti-inflammatory cytokine IL-10 in blood.